drugset / Trial / NCT01889420
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to test the possibility that a combination of three drugs, pomalidomide and everolimus with dexamethasone, may improve patient responses when compared with use of either drug alone, with dexamethasone in refractory/relapsed multiple myeloma.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-06
- Completion
- 2015-07
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Pomalidomide | Other / unclassified | — | Oral |